Invasive Aspergillosis Therapeutics Market Report 2026

The invasive aspergillosis therapeutics market size has grown steadily in recent years. It will grow from $1.13 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing incidence of immunocompromised populations, established clinical guidelines for antifungal therapy, widespread hospital use of amphotericin b, rising prevalence of hematologic malignancies, increased organ transplant procedures.

The invasive aspergillosis therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.42 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to development of novel antifungal drug classes, growing antifungal resistance awareness, expansion of intensive care units globally, increasing fungal infection surveillance programs, improved access to specialty antifungal therapies. Major trends in the forecast period include rising adoption of first-line azole antifungal therapies, growing use of combination antifungal treatment regimens, increasing focus on early diagnosis in immunocompromised patients, expansion of intravenous antifungal use in critical care settings, growing demand for broad-spectrum and lipid-based formulations.

The increasing incidence of fungal infections is expected to drive the growth of the invasive aspergillosis therapeutics market in the coming years. Fungal infections are diseases caused by fungi invading tissues, often impacting the skin, nails, or internal organs. The incidence of fungal infections is rising due to a growing immunocompromised population, climate change, antimicrobial resistance, and increased global travel. Invasive aspergillosis therapeutics help treat fungal infections by employing antifungal agents such as triazoles, echinocandins, and polyenes, which inhibit fungal growth, slow disease progression, and improve survival rates, making early diagnosis essential for managing other invasive fungal infections with similar pathogenic mechanisms. For example, in January 2024, the Center for Infectious Disease Research and Policy, a US-based public health organization, reported that in 2023, over 6.55 million people were affected by invasive fungal infections annually, resulting in more than 3.75 million deaths, with 2.55 million directly caused by these diseases, significantly higher than previous year estimates. Consequently, the increasing incidence of fungal infections is fueling the growth of the invasive aspergillosis therapeutics market.

Major companies in the invasive aspergillosis therapeutics market are focusing on providing effective treatments, including generic drugs, to enhance accessibility, reduce costs, and improve patient outcomes. Generic drugs contain the same active ingredients, dosage, safety, strength, route of administration, quality, and efficacy as their brand-name counterparts but are typically more affordable. For example, in September 2023, BDR Pharmaceutical, an India-based pharmaceutical company, announced the launch of its innovative generic product, Zisavel capsules, aimed at treating invasive aspergillosis and mucormycosis. Zisavel belongs to the isavuconazole class of azole antifungals and offers a vital therapeutic option for these serious fungal infections. The capsules come in a 100 mg dosage and are positioned as the first-line treatment for both conditions. Priced at Rs. 7,992 for a pack of seven capsules, Zisavel costs roughly one-third of the current innovator therapy, providing a cost-effective alternative for patients.

In September 2024, Basilea Pharmaceutica Ltd, a Switzerland-based commercial-stage biopharmaceutical company, signed a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of innovative antifungal and antibacterial therapies. Through this collaboration, Basilea and BARDA aim to advance Basilea’s clinical-stage antifungal candidates, including fosmanogepix and BAL2062, toward regulatory approval, expand treatment options for severe invasive fungal infections such as invasive aspergillosis, support preparedness against resistant pathogens, and promote long-term development sustainability through milestone-based non-dilutive funding. BARDA is a U.S.-based federal agency under the Department of Health and Human Services that supports the advanced development of medical countermeasures for public health emergencies.

Major companies operating in the invasive aspergillosis therapeutics market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gilead Sciences, Astellas Pharma Inc., Shionogi & Co. Ltd, Hikma Pharmaceuticals, Cipla Ltd., Mylan Pharmaceuticals Inc., Basilea Pharmaceutica International Ltd., Pulmocide Ltd., F2G Ltd., Hetero Healthcare, Eugia Pharma, SCYNEXIS Inc., Biosergen AB.

North America was the largest region in the invasive aspergillosis therapeutics market in 2025. The regions covered in the invasive aspergillosis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the invasive aspergillosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the invasive aspergillosis therapeutics market by increasing costs of imported active pharmaceutical ingredients and specialty antifungal formulations. Hospital pharmacies and specialty pharmacies are most affected, particularly in regions dependent on global pharmaceutical supply chains such as north america and europe. Higher tariffs have increased treatment costs and procurement complexity. However, these pressures have encouraged domestic manufacturing, supplier diversification, and investments in cost-efficient antifungal drug development.

The invasive aspergillosis therapeutics market research report is one of a series of new reports that provides invasive aspergillosis therapeutics market statistics, including invasive aspergillosis therapeutics industry global market size, regional shares, competitors with a invasive aspergillosis therapeutics market share, detailed invasive aspergillosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the invasive aspergillosis therapeutics industry. This invasive aspergillosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Invasive aspergillosis therapeutics encompass treatments used to manage severe Aspergillus infections, mainly in immunocompromised patients. These treatments include antifungal drugs such as voriconazole, amphotericin B, and echinocandins, which work to inhibit fungal growth and prevent the spread of infection. In refractory cases, adjunctive therapies like immunomodulators and surgical procedures may also be employed.

The primary drug classes for invasive aspergillosis therapeutics include azoles, echinocandins, polyenes, and others. Azoles are antifungal agents that block the synthesis of ergosterol, a critical component of fungal cell membranes, and are used to treat infections. These therapeutics are administered via oral and intravenous routes and are made available through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies.

The invasive aspergillosis therapeutics market consists of revenues earned by entities by providing services such as hospital & clinical treatment services, diagnostic testing and screening, telemedicine, and remote consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive aspergillosis therapeutics market also includes sales of antifungal medications, adjunctive and supportive therapies, and prophylactic therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.